The DOI matches its Crossref record; 102 of the 102 references it cites were found in a registry or an index.
Fatty Acid Synthase As a Potential Therapeutic Target in Cancer
Open accessAbstract
Fatty acid synthase (FASN) is a key enzyme involved in neoplastic lipogenesis. Overexpression of FASN is common in many cancers, and accumulating evidence suggests that it is a metabolic oncogene with an important role in tumor growth and survival, making it an attractive target for cancer therapy. Early small-molecule FASN inhibitors such as cerulenin, C75 and orlistat have been shown to induce apoptosis in several cancer cell lines and to induce tumor growth delay in several cancer xenograft models but their mechanism is still not well understood. These molecules suffer from pharmacological limitations and weight loss as a side effect that prevent their development as systemic drugs. Several potent inhibitors have recently been reported that may help to unravel and exploit the full potential of FASN as a target for cancer therapy in the near future. Furthermore, novel sources of FASN inhibitors, such as green tea and dietary soy, make both dietary manipulation and chemoprevention potential alternative modes of therapy in the future.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis
Menendez, J. A., & Lupu, R. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2222 · Cited by 2,941
Reduced Food Intake and Body Weight in Mice Treated with Fatty Acid Synthase Inhibitors
Loftus, T. M., Jaworsky, D. E., Frehywot, G. L., Townsend, C. A., Ronnett, G. V., Lane, M. D., & Kuhajda, F. P. (2000) · Science · doi:10.1126/science.288.5475.2379 · Cited by 1,004
Targeting Multiple Signaling Pathways by Green Tea Polyphenol (−)-Epigallocatechin-3-Gallate
Khan, N., Afaq, F., Saleem, M., Ahmad, N., & Mukhtar, H. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3636 · Cited by 820
Platensimycin is a selective FabF inhibitor with potent antibiotic properties
Wang, J., Soisson, S. M., Young, K., Shoop, W., Kodali, S., Galgoci, A., Painter, R., Parthasarathy, G., Tang, Y. S., Cummings, R., et al. (2006) · Nature · doi:10.1038/nature04784 · Cited by 812
Fatty-acid synthase and human cancer: new perspectives on its role in tumor biology
Kuhajda, F. P. (2000) · Nutrition · doi:10.1016/s0899-9007(99)00266-x · Cited by 788
Fatty Acid Synthase and Cancer: New Application of an Old Pathway
Kuhajda, F. P. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4673 · Cited by 647
Structural and functional organization of the animal fatty acid synthase
Smith, S., Witkowski, A., & Joshi, A. K. (2003) · Progress in Lipid Research · doi:10.1016/s0163-7827(02)00067-x · Cited by 643
Increased lipogenesis in cancer cells: new players, novel targets
Swinnen, J. V., Brusselmans, K., & Verhoeven, G. (2006) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/01.mco.0000232894.28674.30 · Cited by 610
Orlistat Is a Novel Inhibitor of Fatty Acid Synthase with Antitumor Activity
Kridel, S. J., Axelrod, F., Rozenkrantz, N., & Smith, J. W. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3645 · Cited by 607
Synthesis and antitumor activity of an inhibitor of fatty acid synthase
Kuhajda, F. P., Pizer, E. S., Li, J. N., Mani, N. S., Frehywot, G. L., & Townsend, C. A. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.7.3450 · Cited by 567
Cited by
The emerging hallmarks of cancer metabolism
Pavlova, N. N., & Thompson, C. B. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2015.12.006 · Cited by 5,926
Cancer metabolism: a therapeutic perspective
Martinez-Outschoorn, U. E., Peiris-Pagés, M., Pestell, R. G., Sotgia, F., & Lisanti, M. P. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.60 · Cited by 1,505
Targeting cancer metabolism: a therapeutic window opens
Vander Heiden, M. G. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3504 · Cited by 1,411
Lipid metabolic reprogramming in cancer cells
Beloribi-Djefaflia, S., Vasseur, S., & Guillaumond, F. (2016) · Oncogenesis · doi:10.1038/oncsis.2015.49 · Cited by 1,398
Targeting cellular metabolism to improve cancer therapeutics
Zhao, Y., Butler, E. B., & Tan, M. (2013) · Cell Death & Disease · doi:10.1038/cddis.2013.60 · Cited by 989
Lipid metabolism reprogramming and its potential targets in cancer
Cheng, C., Geng, F., Cheng, X., & Guo, D. (2018) · Cancer Communications · doi:10.1186/s40880-018-0301-4 · Cited by 850
Lipid metabolism in cancer: New perspectives and emerging mechanisms
Broadfield, L. A., Pane, A. A., Talebi, A., Swinnen, J. V., & Fendt, S.-M. (2021) · Developmental Cell · doi:10.1016/j.devcel.2021.04.013 · Cited by 758
Bensaad, K., Favaro, E., Lewis, C. A., Peck, B., Lord, S., Collins, J. M., Pinnick, K. E., Wigfield, S., Buffa, F. M., Li, J.-L., et al. (2014) · Cell Reports · doi:10.1016/j.celrep.2014.08.056 · Cited by 665
Metabolomics in cancer research and emerging applications in clinical oncology
Schmidt, D. R., Patel, R., Kirsch, D. G., Lewis, C. A., Vander Heiden, M. G., & Locasale, J. W. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21670 · Cited by 648
Metabolic dysregulation and emerging therapeutical targets for hepatocellular carcinoma
Du, D., Liu, C., Qin, M., Zhang, X., Xi, T., Yuan, S., Hao, H., & Xiong, J. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.09.019 · Cited by 643
Fatty acid oxidation and carnitine palmitoyltransferase I: emerging therapeutic targets in cancer
Qu, Q., Zeng, F., Liu, X., Wang, Q. J., & Deng, F. (2016) · Cell Death & Disease · doi:10.1038/cddis.2016.132 · Cited by 545
Beauchemin, N., & Arabzadeh, A. (2013) · Cancer and Metastasis Reviews · doi:10.1007/s10555-013-9444-6 · Cited by 538
Fatty Acid Synthase: An Emerging Target in Cancer
Fhu, C. W., & Ali, A. (2020) · Molecules · doi:10.3390/molecules25173935 · Cited by 392
Molecular Pathways: Fatty Acid Synthase
Jones, S. F., & Infante, J. R. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0126 · Cited by 306
Ventura, R., Mordec, K., Waszczuk, J., Wang, Z., Lai, J., Fridlib, M., Buckley, D., Kemble, G., & Heuer, T. S. (2015) · EBioMedicine · doi:10.1016/j.ebiom.2015.06.020 · Cited by 301
Falchook, G., Infante, J., Arkenau, H.-T., Patel, M. R., Dean, E., Borazanci, E., Brenner, A., Cook, N., Lopez, J., Pant, S., et al. (2021) · EClinicalMedicine · doi:10.1016/j.eclinm.2021.100797 · Cited by 296
Fatty acid synthase (FASN) as a therapeutic target in breast cancer
Menendez, J. A., & Lupu, R. (2017) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2017.1381087 · Cited by 293
The fat side of prostate cancer
Zadra, G., Photopoulos, C., & Loda, M. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2013.03.010 · Cited by 291
Self-citationMetabolic reprogramming in cancer: Mechanisms and therapeutics
Nong, S., Han, X., Xiang, Y., Qian, Y., Wei, Y., Zhang, T., Tian, K., Shen, K., Yang, J., & Ma, X. (2023) · MedComm · doi:10.1002/mco2.218 · Cited by 287
O-GlcNAcylation in Cancer Biology: Linking Metabolism and Signaling
Ferrer, C. M., Sodi, V. L., & Reginato, M. J. (2016) · Journal of Molecular Biology · doi:10.1016/j.jmb.2016.05.028 · Cited by 267
TGF-β signaling in the tumor metabolic microenvironment and targeted therapies
Shi, X., Yang, J., Deng, S., Xu, H., Wu, D., Zeng, Q., Wang, S., Hu, T., Wu, F., & Zhou, H. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01349-6 · Cited by 262
Lin, H.-P., Cheng, Z.-L., He, R.-Y., Song, L., Tian, M.-X., Zhou, L.-S., Groh, B. S., Liu, W.-R., Ji, M.-B., Ding, C., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-1597 · Cited by 150
Heuer, T. S., Ventura, R., Mordec, K., Lai, J., Fridlib, M., Buckley, D., & Kemble, G. (2017) · EBioMedicine · doi:10.1016/j.ebiom.2016.12.012 · Cited by 136
Pang, M., Su, K., & Li, M. (2021) · doi:10.1101/2021.11.28.470212 · Cited by 130
Zaytseva, Y. Y., Rychahou, P. G., Le, A.-T., Scott, T. L., Flight, R. M., Kim, J. T., Harris, J., Liu, J., Wang, C., Morris, A. J., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.25361 · Cited by 123
From obesity to cancer: a review on proposed mechanisms
Tahergorabi, Z., Khazaei, M., Moodi, M., & Chamani, E. (2016) · Cell Biochemistry and Function · doi:10.1002/cbf.3229 · Cited by 118
Progress toward Overcoming Hypoxia-Induced Resistance to Solid Tumor Therapy
Reginato, M., & Karakashev, S. (2015) · Cancer Management and Research · doi:10.2147/cmar.s58285 · Cited by 95
Targeting endothelial metabolism for anti-angiogenesis therapy: A pharmacological perspective
Missiaen, R., Morales-Rodriguez, F., Eelen, G., & Carmeliet, P. (2017) · Vascular Pharmacology · doi:10.1016/j.vph.2017.01.001 · Cited by 58
Tomek, K., Wagner, R., Varga, F., Singer, C. F., Karlic, H., & Grunt, T. W. (2011) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-10-0467 · Cited by 64
Acetyl-CoA metabolism as a therapeutic target for cancer
Chen, G., Bao, B., Cheng, Y., Tian, M., Song, J., Zheng, L., & Tong, Q. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.115741 · Cited by 54
Wang, C. J., Li, D., Danielson, J. A., Zhang, E. H., Dong, Z., Miller, K. D., Li, L., Zhang, J.-T., & Liu, J.-Y. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.03.026 · Cited by 51
Metadata
- Authors
- Flavin, R., Peluso, S., Nguyen, P. L., & Loda, M.
- Venue
- Future Oncology
- Publisher
- Informa UK Limited
- Published
- 2010-04-07
- Volume
- 6
- Issue
- 4
- Pages
- 551-562
- ISSN
- 1479-6694 (ISSN-L)
- 1744-8301
- OpenAlex
- W1986234170
- Cited by
- 545
- References
- 102
- FWCI
- 5.15
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.